Profound Medical Corp. PROF
Set alert
At close · Oct 30
After hours · Oct 30, 4:33 PM ET
- YTD
- -16.52%
- 1 year
- +7.35%
- Open
- 5.98
- Prev close
- 5.86
- Mkt cap
- 240.02M
- Vol
- 475.51K
- Avg vol
- 185.65K
- EPS
- -0.99
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 5.88
- High
- 6.63
- Forward P/E
- -7.95
- Beta
- 0.83
- Short ratio
- 7.87
- Inst. own
- 35.99%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 8, 2024
- 50-d avg
- 7.73
- 200-d avg
- 8.29
- 1y target
- 15.30
Key statistics
- Market cap
- 210.20M
- Enterprise value
- 157.76M
- Trailing P/E
- 0.00
- Forward P/E
- -7.95
- PEG ratio
- 0.00
- Price / sales
- 23.40
- Price / book
- 5.55
- EPS (TTM)
- -1.34
- Beta
- 0.83
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 8.98M
- Revenue growth
- 63.90%
- Free cash flow
- -14.79M
- Total cash
- 27.12M
- Total debt
- 6.23M
- Return on equity
- -90.17%
- Shares outstanding
- 30.03M
- Short % of float
- 0.00%
- 50-day average
- 7.73
- 200-day average
- 8.29
Analyst view
Consensus: strong buy
- Target (low)
- 12.00
- Target (mean)
- 15.30
- Target (high)
- 18.00
- Strong buy0
- Buy5
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 8, 2024
Expected Aug 8, 2024. Consensus EPS estimate -0.345.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 7, 2024 | Sep 1, 2024 | -0.33 | -0.38 | -0.05 | -15.15% |
| Aug 8, 2024 | Jun 1, 2024 | -0.28 | -0.28 | 0.00 | 0.00% |
| Aug 8, 2024 | Jun 1, 2024 | -0.28 | — | — | — |
| May 9, 2024 | Mar 1, 2024 | -0.31 | — | — | — |
| May 9, 2024 | Mar 1, 2024 | -0.31 | -0.26 | +0.05 | +16.13% |
| Mar 7, 2024 | Dec 1, 2023 | -0.28 | -0.42 | -0.14 | -50.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jul 16, 2024 | Stifel | up | Hold | Buy |
| Mar 11, 2024 | Alliance Global Partners | main | Buy | Buy |
| Mar 8, 2024 | Stifel | main | Hold | Hold |
| Jan 4, 2024 | Alliance Global Partners | main | Buy | Buy |
| Nov 28, 2023 | Stifel | init | — | Hold |
| Aug 4, 2023 | Raymond James | down | Strong Buy | Outperform |
About Profound Medical Corp.
Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum. The company also offers Sonalleve, which combines real-time MRI and thermometry for the treatment of uterine fibroids, adenomyotic tissue, palliative pain treatment of bone metastases, osteoid osteoma, and management of benign tumors. Profound Medical Corp. is headquartered in Mississauga, Canada.
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- Canada
- Website
- profoundmedical.com
News
- 12 Health Care Stocks Moving In Friday's Intraday Session
- Wall Street Analysts Believe Profound Medical (PROF) Could Rally 89.93%: Here's is How to Trade
- Profound Medical Strikes Supply, Distribution Deal With iMRI Division Of Cook Medical To Expand Sales Of TULSA-PRO System In U.S.
- Profound Medical and Cook Medical's iMRI Division Partner to Expand U.S. TULSA-PRO® Sales Channels and Drive Recurring Revenue Growth
- Emmy-Award Winning Television Host Montel Williams to Join Next ‘Let's Huddle' Webinar
- Does Profound Medical (PROF) Have the Potential to Rally 58.77% as Wall Street Analysts Expect?
- TULSA Abstracts at the 15th Interventional MRI Symposium Strengthen Real-World Evidence, Clinical Differentiation, and Platform Expansion Opportunity
- Strength Seen in Profound Medical (PROF): Can Its 21.7% Jump Turn into More Strength?
- Profound Medical Signs Agreement With Telix Pharmaceuticals To Educate Urologists, Radiologists, Nuclear Medicine Physicians, Prostate Cancer Centers Over Roles Of Telix’s Advanced Prostate-Specific Membrane Antigen
- Profound Medical and Telix Pharmaceuticals Enter Co-Education Agreement to Advance PSMA-Informed Prostate Care
Your note
Sign in to keep a note on PROF — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| FIL LTD | 5.11% | 1,535,000 | 10.74M | Sep 29, 2024 |
| Gagnon Securities, LLC | 4.89% | 1,467,247 | 10.27M | Sep 29, 2024 |
| Letko, Brosseau & Associates Inc. | 3.99% | 1,198,775 | 8.39M | Sep 29, 2024 |
| Raymond James Financial Services Advisors, Inc. | 2.53% | 760,457 | 5.32M | Sep 29, 2024 |
| Timelo Investment Management Inc. | 2.50% | 751,807 | 5.26M | Sep 29, 2024 |
| Gagnon Advisors, LLC | 2.49% | 747,226 | 5.23M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Royce Micro-Cap Fund | 0.76% | 227,937 | 1.60M | Sep 29, 2024 |
| Royce Micro Cap Trust | 0.63% | 189,100 | 1.32M | Sep 29, 2024 |
| Royce Capital Fund-Micro-Cap Portfolio | 0.33% | 100,163 | 701.14K | Sep 29, 2024 |
| Royce Small-Cap Fund | 0.17% | 52,098 | 364.69K | Sep 29, 2024 |
| Fidelity NASDAQ Composite Index Fund | 0.05% | 14,049 | 98.34K | Oct 30, 2024 |
| Dimensional ETF Tr-Dimensional International Small Cap ETF | 0.00% | 1,188 | 8.32K | Jul 30, 2024 |